MannKind Announces Clinical Data for Conference

MannKind Announces Clinical Data for Conference

By, Admin 7 March 2024

MannKind announces new clinical data from INHALE-3 study; to present at International Conference on ATTD in Florence on March 6-9

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that new clinical data from the INHALE-3 study first meal challenge will be presented at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 6-9.  INHALE-3 study is a phase 4 US clinical trial evaluating inhaled insulin (plus basal) vs. standard of care. 

Upcoming Presentation by the Protocol Chair

Dr. Irl B. Hirsch, Professor of Medicine and Diabetes Treatment and Teaching Chair at the University of Washington and the INHALE-3 Study Protocol Chair, will provide an oral presentation focused on findings from a standardized meal challenge, including: Post-prandial glucose with inhaled insulin vs. subcutaneous rapid-acting analogue (RAA); Glucose outcomes including AUC and time to peak during the first two hours and beyond; Frequency of post-meal hypoglycemia in both groups.

MannKind Corporation on INHALE-3 Data

  • “We are looking forward to the first slice of INHALE-3 data being presented here that builds upon findings from our pilot ABC study shared at last year’s ATTD Conference,” said Dr. Kevin Kaiserman, senior vice president, clinical development and medical affairs for MannKind Corporation. 
  • “With ABC and this trial, we used a higher initial conversion dose for inhaled insulin than in our current label. In the ABC study, this conversion dose produced significantly lowered post-prandial glucose levels that peaked 30 minutes sooner than standard of care. 
  • At ATTD, we are presenting INHALE-3’s meal challenge with a much larger comparator group across treatment regimens.” 

About INHALE-3

  • INHALE-3 is a 17-week randomized controlled trial with a 13-week extension. 
  • The study randomly assigned participants over 18 years of age with T1D who are using MDI, an AID system, or a pump without automation to either continue their standard of care or adopt an insulin regimen of a daily basal injection plus Afrezza at mealtimes. 
  • Both arms utilized continuous glucose monitoring to assess mealtime control and A1c levels.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!